Media.Player

Clinical Immunoassays to Determine Concentration of Monoclonal Antibodies

技術優勢

Generalizable to any monoclonal antibody or other recombinant protein biologic therapy Easier than current methods Developed two specific assays, one for rituximab and one for alemtuzumab Phage displayed peptide libraries used to select peptide sequences recognized by the specific monoclonal antibody Synthetic biotinylated peptides produced based on these sequences High sensitivity of bead based assay (less then 0.1 µg/ml) with extremely low background ELISA protocol on streptavidin - coated plates sufficient for higher antibody concentrations (>1.0 µg/ml)

技術應用

There are over 100 monoclonal antibodies developed for current therapies. The peptide-based assays are ideal for the development of validated clinical assays and monoclonal antibodies pharmacokinetics analyses.

詳細技術說明

This technology is a general method to develop assays to detect the circulating concentration of monoclonal antibodies in patients that have received them as treatment for cancer or other diseases. The method is applicable to any monoclonal antibody or other recombinant protein biologic therapy. In addition, two specific assays, one for rituximab and one for alemtuzumab, have been developed. Synthetic biotinylated peptides have been produced based on the sequence derived from phage displayed peptide libraries. UCSD researchers have then developed an optimized ELISA protocol, and a complementary bead based immunoassay. The enhanced sensitivity of the bead based assay is ideal for detecting very low levels of the targeted antibody, while conventional ELISA is sufficient when the targeted antibody is expected to be higher.

*Abstract

Monoclonal antibodies are a powerful form of treatment for many cancers and other proliferative diseases. The development of treatment schedules is a difficult process since the desired in vivo levels must be extrapolated from in vitro studies, the route of administration can be very influential, and each monoclonal antibody may have its own biological interactions. Existing methods require the production of expensive custom and sometimes difficult to produce biological reagents.
There is a need, therefore, of simple, accurate, and sensitive assays to understand the pharmacokinetics of monoclonal antibodies treatments.

*IP Issue Date

Feb 2, 2016

*Principal Investigation

Name: Thomas Kipps

Department:

Name: Andrew Kummel

Department:

Name: Bradley Messmer

Department:

Name: Manuel Ruidiaz

Department:

Name: Ana Sanchez

Department:

附加資料

Patent Number: US20110124020A1
Application Number: US2010934624A
Inventor: Kipps, Thomas J. | Messmer, Bradley T. | Sanchez, Ana B. | Kummel, Andrew C. | Ruidiaz, Manuel
Priority Date: 27 Mar 2008
Priority Number: US20110124020A1
Application Date: 10 Jan 2011
Publication Date: 26 May 2011
IPC Current: G01N003353
US Class: 43500793 | 43500792 | 43500794 | 436501
Title: Methods for Detecting Antibodies
Usefulness: Methods for Detecting Antibodies
Summary: The method is useful for detecting an antibody not complexed to antigen in a biological sample suspected of containing such antibody (claimed).
Novelty: Detecting an antibody not complexed to antigen in a biological sample, comprises synthesizing peptides with a mimetope, contacting the peptide with the biological sample, and allowing binding of the peptides with the antibody

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

9250233

其他

State Of Development

This technology is offered exclusively or nonexclusively in the US and/or worldwide territories. A commercial sponsor for potential future research is sought.

Other Information

UCSD Researcher:
Dr. Thomas Kipps, M.D., Ph.D., is a professor of medicine, the chief of the Division of Hematology/ Oncology at the UCSD School of Medicine, and the Deputy Director of research at the Moores UCSD Cancer Center. He is also the director of the National CLL Research Consortium and associate director of the UCSD Gene Therapy Program.

Dr. Bradley Messmer, Ph.D., is assistant project scientist at the UCSD Moores Cancer Center.

Related Materials

Thomas J. Kipps, MD, PhD
Bradley Messmer, PhD

Tech ID/UC Case

19801/2008-226-0

Related Cases

2008-226-0

國家/地區

美國